Demos Could Result From ‘Most Favored Nation’ Order

The Trump administration’s long-awaited executive order that seeks to tie U.S. drug prices to costs in other countries may represent more presidential campaign talking points than real policy that will take effect quickly. But analysts expect that the overarching issue of drug pricing will stick around, regardless of which candidate wins on Nov. 3.

For example, the executive order signals that the administration could pursue price caps for select Medicare Part B and D drugs in a possible second term. The order calls for demonstration projects to test “most favored nation” pricing in Parts B and D.

© 2021 MMIT

Freelance Reporter Freelance Reporter

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-radar-on-drug-benefits-Merck-COVID-19-Drug-Could-Gain-Emergency-Use-Authorization.jpg
October 14

Merck COVID-19 Drug Could Gain Emergency Use Authorization

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-radar-on-drug-benefits-More-MA-PD-PDP-Members-Will-Be-in-4-Star-Plans-in-2022.jpg
October 14

More MA-PD, PDP Members Will Be in 4-Star Plans in 2022

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-radar-on-drug-benefits-PhRMA-Blasts-Poll-About-Govt-Drug-Price-Negotiation-Support.jpg
October 14

PhRMA Blasts Poll About Gov’t Drug Price Negotiation Support

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today